Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
64 pending office actions • 24 clients • 62 examiners • 37 art units • 0 of 64 (0%) have an AI response strategy ready
VIKSNINS HARRIS PADYS MALEN LLP operates in Biotechnology & Pharmaceuticals, with 3291 career applications. The firm has a resolved allowance rate pct of 76.49. This rate reflects its success in the Biotechnology & Pharmaceuticals prosecution environment. Practitioners can use the 3291 career applications to evaluate the firm's historical outcomes. These metrics offer a basis for setting expectations for future filings in this technical field. The 76.49 resolved allowance rate pct provides a measure of success for applications managed by the firm.
The firm has 49 pending office actions. Its avg office actions per allowance is 3.46. This 3.46 avg office actions per allowance reflects the number of examiner interactions typically required to reach an allowance. With 49 pending office actions, the firm continues to manage its active cases. The 3.46 avg office actions per allowance helps practitioners estimate the resources needed for the examination phase. The 76.49 resolved allowance rate pct and the 49 pending office actions provide a view of the firm's performance.
Based on the USPTO statutory response window for each pending office action. 23 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 23 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 7 (11%) |
| §103 only | 12 (19%) |
| §102 only | 1 (2%) |
| §112 only | 6 (9%) |
| Double-patenting only | 1 (2%) |
| Double-patenting + other | 8 (12%) |
| Multi-statute (no §101) | 28 (44%) |
| No statute on record | 1 (2%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BURKETT, DANIEL JOHN | 2 | 62.6% | +33.2% |
| YOUNGBLOOD, WILLIAM JUSTIN | 2 | 60.0% | +41.7% |
| PRINCE JR, FREDDIE GARY | 1 | 79.0% | +20.7% |
| NUR, ABDULLAHI | 1 | 88.2% | +6.1% |
| HASTINGS, ALISON AZAR | 1 | 63.5% | +40.2% |
| ROBINSON, KEITH O NEAL | 1 | 91.6% | +3.8% |
| BAIG, RUMAISA RASHID | 1 | 34.0% | +33.2% |
| BERRIOS, JENNIFER A | 1 | 37.0% | +49.8% |
| DONOHUE, SEAN R | 1 | 41.4% | +21.0% |
| ABDALHAMEED, MANAHIL MIRGHANI ALI | 1 | 50.3% | +38.2% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19228322 | HYPERSPECTRAL IMAGING FOR EARLY DETECTION OF ALZHEIMER'S DISEASE | NUR, ABDULLAHI | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18110292 | METHOD FOR PREPARING ACTIVATED CARBON | MENON, KRISHNAN S | 191d overdue |
| 18634406 | SYNTHETIC GENOMIC SAFE HARBORS AND METHODS THEREOF | SULLIVAN, STEPHANIE LAUREN | 131d overdue |
| 17928535 | METHOD FOR PROVIDING CORROSION PROTECTION TO A PRESSURIZED WATER-STEAM SYSTEM | DIAZ, MATTHEW R | 51d overdue |
| 18639608 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | MCDOWELL, BRIAN E | 3d overdue |
| 18274412 | INHIBITION OF DEGRANULATION OF NEUTROPHIL CELLS IN COVID-19 PATIENTS | BANERJEE, KOYELI | 13d |
| 18008391 | IDENTIFICATION OF LOW-DENSITY INFLAMMATORY NEUTROPHILS IN SEVERE COVID-19 PATIENTS | WANG, RUIXUE | 20d |
| 18237360 | METALLOENZYME MODULATORS | PIHONAK, SARAH | 27d |
| 18276823 | ANTI-TRANSFERRIN RECEPTOR FUSION PROTEINS AND METHODS OF USE THEREOF | LU, CHENG | 46d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18868551 | Untitled | PRINCE JR, FREDDIE GARY | — |
| 19191629 | METHODS AND COMPOUNDS USEFUL IN THE SYNTHESIS OF AN AAK1 INHIBITOR | HASTINGS, ALISON AZAR | — |
| 18958741 | SYNTHETIC PROCESSES AND SYNTHETIC INTERMEDIATES | BURKETT, DANIEL JOHN | — |
| 18903209 | EXTERNAL FONTANELLE INTRACRANIAL LIGHT (EFIL) DEVICE | BAIG, RUMAISA RASHID | — |
| 18852384 | VOLATILE HDAC INHIBITORS FOR THERAPEUTIC AND PLANT APPLICATIONS | BERRIOS, JENNIFER A | — |
| 18897158 | METHODS OF TREATING TYPE 1 DIABETES AND KIDNEY DISEASE | YOUNGBLOOD, WILLIAM JUSTIN | — |
| 18896069 | COMPOSITIONS FOR CHELATING METALS AT LOW TEMPERATURES | DONOHUE, SEAN R | — |
| 18846873 | THERAPEUTIC COMPOUND AND SALTS | ABDALHAMEED, MANAHIL MIRGHANI ALI | — |
| Art Unit | Apps |
|---|---|
| 1624 | 3 |
| 1625 | 2 |
| 1613 | 2 |
| 1791 | 2 |
| 1635 | 2 |
| 1699 | 2 |
| 1629 | 2 |
| 1641 | 2 |
| 1642 | 2 |
| 1792 | 2 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18868551 | Untitled | The Regents of the University of California | PRINCE JR, FREDDIE GARY | §101§103§112Other | Final Rejection | — | Pending | ||
| 19228322 | HYPERSPECTRAL IMAGING FOR EARLY DETECTION OF ALZHEIMER'S DISEASE | Regents Of The University Of Minnesota | NUR, ABDULLAHI | §103Other | Non-Final OA | — | Pending | Jun 04, 2025 | |
| 19191629 | METHODS AND COMPOUNDS USEFUL IN THE SYNTHESIS OF AN AAK1 INHIBITOR | Lexicon Pharmaceuticals, Inc. | HASTINGS, ALISON AZAR | DP | Non-Final OA | — | Pending | Apr 28, 2025 | |
| 18961937 | COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS BY VIRUS PARTICLES IN PLANTS | The Regents of the University of California | ROBINSON, KEITH O NEAL | 1661 | §103§112Other | Non-Final OA | — | Pending | Nov 27, 2024 |
| 18958741 | SYNTHETIC PROCESSES AND SYNTHETIC INTERMEDIATES | Taxis Pharmaceuticals, Inc. | BURKETT, DANIEL JOHN | 1625 | §102§112DP | Non-Final OA | — | Pending | Nov 25, 2024 |
| 18903209 | EXTERNAL FONTANELLE INTRACRANIAL LIGHT (EFIL) DEVICE | Rutgers, The State University Of New Jersey | BAIG, RUMAISA RASHID | §102§103§112 | Non-Final OA | — | Pending | Oct 01, 2024 | |
| 18852384 | VOLATILE HDAC INHIBITORS FOR THERAPEUTIC AND PLANT APPLICATIONS | The Regents of the University of California | BERRIOS, JENNIFER A | 1613 | §101§103§112 | Non-Final OA | — | Pending | Sep 27, 2024 |
| 18897158 | METHODS OF TREATING TYPE 1 DIABETES AND KIDNEY DISEASE | Lexicon Pharmaceuticals, Inc. | YOUNGBLOOD, WILLIAM JUSTIN | §102§103§112 | Non-Final OA | — | Pending | Sep 26, 2024 | |
| 18896069 | COMPOSITIONS FOR CHELATING METALS AT LOW TEMPERATURES | UNIVERSITY OF IOWA RESEARCH FOUNDATION | DONOHUE, SEAN R | 1618 | §102§103§112DP | Non-Final OA | — | Pending | Sep 25, 2024 |
| 18846873 | THERAPEUTIC COMPOUND AND SALTS | Regents Of The University Of Minnesota | ABDALHAMEED, MANAHIL MIRGHANI ALI | §102§103§112 | Non-Final OA | — | Pending | Sep 13, 2024 | |
| 18811912 | Method for Producing Protein Crisps and Products Produced Thereby | Glanbia Dairy Nutrition Limited | DUBOIS, PHILIP A | 1791 | §102§103 | Final Rejection | — | Pending | Aug 22, 2024 |
| 18833738 | Textured Plant Protein Pasta Product and Method | Glanbia Dairy Nutrition Limited | TRAN, LIEN THUY | §103§112 | Non-Final OA | — | Pending | Jul 26, 2024 | |
| 18728925 | PROCESS FOR SYNTHESIS OF GALBULIMIMA ALKALOID 18 AND COMPOUNDS USEFUL AS OPIOID RECEPTOR ANTAGONISTS AND AGONISTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | YOUNGBLOOD, WILLIAM JUSTIN | §112 | Non-Final OA | — | Pending | Jul 15, 2024 | |
| 18724911 | METHODS FOR IMPROVING PROTEIN DELIVERY TO PLANT CELLS BY BIOLISTICS | The Regents of the University of California | SHEN, YANXIN NMN | 1663 | §103§112 | Non-Final OA | — | Pending | Jun 27, 2024 |
| 18722252 | ANTI-MASP-2 ANTIBODY, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Shenyang Sunshine Pharmaceutical Co., Ltd. | STEPHENS, AMELIA CAROLE | 1645 | §102§103§112Other | Non-Final OA | — | Pending | Jun 20, 2024 |
| 18669075 | BIOMARKERS AND METHODS FOR DETECTION OF SEIZURES AND EPILEPSY | Cognizance Biomarkers, Inc. | ORWIG, KEVIN S | 3991 | Other | Non-Final OA | — | Pending | May 20, 2024 |
| 18662929 | NHE3-BINDING COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | Ardelyx, Inc. | SHIAO, REI TSANG | §112DP | Non-Final OA | — | Pending | May 13, 2024 | |
| 18648062 | THERAPEUTIC COMPOUNDS | Rutgers, The State University Of New Jersey | CORNET, JEAN P | §102§103§112 | Non-Final OA | — | Pending | Apr 26, 2024 | |
| 18705175 | TOLL-LIKE RECEPTOR AGONISTS AND ANTAGONISTS AND USES THEREOF | Regents Of The University Of Minnesota | ONDACHI, PAULINE WANJIKU MUCH | §103DP | Non-Final OA | — | Pending | Apr 26, 2024 | |
| 18639608 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | Regents Of The University Of Minnesota | MCDOWELL, BRIAN E | 1624 | §102§103 | Non-Final OA | 3d overdue | Pending | Apr 18, 2024 |
| 18634406 | SYNTHETIC GENOMIC SAFE HARBORS AND METHODS THEREOF | The Regents of the University of California | SULLIVAN, STEPHANIE LAUREN | 1635 | §102§103 | Final Rejection | 131d overdue | Pending | Apr 12, 2024 |
| 18633908 | THERAPEUTIC COMPOUNDS | Regents Of The University Of Minnesota | MILLER, DALE R | §103 | Non-Final OA | — | Pending | Apr 12, 2024 | |
| 18700140 | IMPROVED CEREBRAL ANGIOGRAPHY CATHETER | Rutgers, The State University Of New Jersey | FERNANDEZ, KATHERINE L | 3798 | §103 | Non-Final OA | — | Pending | Apr 10, 2024 |
| 18613381 | USE OF SOTAGLIFLOZIN FOR THE TREATMENT OF PATIENTS WITH TYPE 1 DIABETES MELLITUS | Lexicon Pharmaceuticals, Inc. | CRAIGO, BAHAR ALAWI | 1699 | §101§102§112 | Non-Final OA | — | Pending | Mar 22, 2024 |
| 18593314 | CONJUGATES AND METHODS OF USE THEREOF | Regents Of The University Of Minnesota | BOWERS, ERIN M | 1653 | §102§103 | Non-Final OA | — | Pending | Mar 01, 2024 |
| 18424215 | FORTIFIED CONFECTION COMPOSITIONS | Glanbia Dairy Nutrition Limited | STULII, VERA | 1791 | §102§112 | Non-Final OA | — | Pending | Jan 26, 2024 |
| 18403891 | HIGHLY FLUORINATED COMPOUNDS FOR 19F MRI-BASED THERMOMETRY | Regents Of The University Of Minnesota | BRAZIN, JACQUELINE | §102§112 | Non-Final OA | — | Pending | Jan 04, 2024 | |
| 18572411 | THERAPEUTIC COMPOUNDS | Taxis Pharmaceuticals, Inc. | CHENG, KAREN | 1623 | §102§103§112 | Non-Final OA | — | Pending | Dec 20, 2023 |
| 18517049 | PHARMACOLOGICAL DEPLETION OF HEME FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROME | The Scripps Research Institute | NEAGU, IRINA | 1629 | §102§103 | Non-Final OA | — | Pending | Nov 22, 2023 |
| 18381799 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | Ardelyx, Inc. | SONG, JIANFENG | 1613 | §103DPOther | Non-Final OA | — | Pending | Oct 19, 2023 |
| 18286955 | Glycan Targets of Serum IgG and IgM Antibodies | Regents Of The University Of Minnesota | WEN, SHARON X | 1641 | §103 | Non-Final OA | — | Pending | Oct 13, 2023 |
| 18372535 | CATALYSTS | The Regents of the University of California | SPIES, BRADLEY R | 1742 | §102§103 | Non-Final OA | — | Pending | Sep 25, 2023 |
| 18283071 | 2-AMINO-4-CARBOXAMIDE-BENZAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. | METCALF, MATTHEW CURRAN | 1647 | §103DP | Non-Final OA | — | Pending | Sep 20, 2023 |
| 18550500 | ANTIVIRAL PRODRUGS OF ETV AND FORMULATIONS THEREOF | The Scripps Research Institute | DEKARSKE, MADELINE MCGUIRE | 1622 | §103 | Final Rejection | 33d | Pending | Sep 14, 2023 |
| 18548635 | HETEROBIFUNCTIONAL COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION AND METHODS FOR THEIR USE | The Scripps Research Institute | CHANDRAKUMAR, NIZAL S | 1625 | §103§112 | Final Rejection | — | Pending | Sep 01, 2023 |
| 18279380 | METHODS OF ENHANCING ANTIBODY THERAPIES | UNIVERSITY OF IOWA RESEARCH FOUNDATION | ALSOMAIRY, SARAH ABDOALATIF | 1646 | §112 | Final Rejection | 23d overdue | Pending | Aug 29, 2023 |
| 18237069 | SYSTEM, METHOD AND CATHETER FOR PITUITARY AND BRAIN IMPLANTATION | Academisch Ziekenhuis Leiden (H.O.D.N. Lumc) | PORTER, JR, GARY A | 3796 | §101§102§103§112Other | Non-Final OA | — | Pending | Aug 23, 2023 |
| 18237360 | METALLOENZYME MODULATORS | Regents Of The University Of Minnesota | PIHONAK, SARAH | 1627 | §102§112 | Non-Final OA | 27d | Pending | Aug 23, 2023 |
| 18277444 | ARTIFICIAL DNA REPLISOME AND METHODS OF USE THEREOF | Regents Of The University Of Minnesota | FRONDA, CHRISTIAN L | 1652 | §103§112 | Non-Final OA | 70d | Pending | Aug 16, 2023 |
| 18546217 | SMALL MOLECULE ACTIVATORS OF YAP TRANSCRIPTIONAL ACTIVITY FOR REGENERATIVE ORGAN REPAIR | The Scripps Research Institute | BRAUN, MADELINE E | 1624 | §103§112 | Non-Final OA | — | Pending | Aug 11, 2023 |
| 18276823 | ANTI-TRANSFERRIN RECEPTOR FUSION PROTEINS AND METHODS OF USE THEREOF | Denali Therapeutics Inc. | LU, CHENG | 1642 | §102§103§112Other | Non-Final OA | 46d | Pending | Aug 10, 2023 |
| 18228422 | SELECTIVE BRD4-DEGRADER MOLECULES | Regents Of The University Of Minnesota | BURKETT, DANIEL JOHN | 1624 | §112 | Final Rejection | — | Pending | Jul 31, 2023 |
| 18274907 | A PROCESS FOR PREPARING A VEGAN EDIBLE PRODUCT FROM EDIBLE NON-ANIMAL PROTEINS | BK Giulini GmbH | BEKKER, KELLY JO | 1792 | §103§112 | Final Rejection | 84d | Pending | Jul 28, 2023 |
| 18274863 | A PROCESS FOR PREPARING A VEGAN EDIBLE PRODUCT FROM EDIBLE NON-ANIMAL PROTEINS | BK Giulini GmbH | GWARTNEY, ELIZABETH A | 1759 | §103 | Final Rejection | 35d overdue | Pending | Jul 28, 2023 |
| 18274412 | INHIBITION OF DEGRANULATION OF NEUTROPHIL CELLS IN COVID-19 PATIENTS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. | BANERJEE, KOYELI | 1658 | §103§112 | Final Rejection | 13d | Pending | Jul 26, 2023 |
| 18215463 | MATERIALS AND METHODS FOR WATER PURIFICATION | UNIVERSITY OF NOTRE DAME DU LAC | BASS, DIRK R | 1779 | §102 | Final Rejection | — | Pending | Jun 28, 2023 |
| 18035695 | TARGETED CONJUGATES COMPRISING MODIFIED SIRNA | Arbutus Biopharma Corporation | TATGE, LEXUS MARC | 1637 | §102§103§112DP | Non-Final OA | — | Pending | May 05, 2023 |
| 18141728 | MASKED SINGLE-DOMAIN ANTIBODIES AND METHODS THEREOF | Regents Of The University Of Minnesota | TAYLOR, LIA ELAN | 1641 | §112 | Final Rejection | 19d | Pending | May 01, 2023 |
| 18032768 | METHODS FOR IMPROVING PLANT GROWTH AND CROP YIELD BY USING COMPOUNDS OF TRISULPHIDE OR TETRASULPHIDE | UNIVERSITY OF IOWA RESEARCH FOUNDATION | PAK, JOHN D | 1699 | §102§103§112 | Non-Final OA | — | Pending | Apr 19, 2023 |
| 18120204 | MICRORNA INHIBITOR SYSTEM AND METHODS OF USE THEREOF | UNIVERSITY OF IOWA RESEARCH FOUNDATION | MEYERING, SHABANA SHABBEER | 1635 | §101§112 | Non-Final OA | — | Pending | Mar 10, 2023 |
| 18110292 | METHOD FOR PREPARING ACTIVATED CARBON | The Regents of the University of California | MENON, KRISHNAN S | 1777 | §102§103 | Final Rejection | 191d overdue | Pending | Feb 15, 2023 |
| 18017541 | PYRAZOLOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. | DAHLIN, HEATHER RAQUEL | 1629 | §112 | Final Rejection | 2d overdue | Pending | Jan 23, 2023 |
| 18010108 | BIOMARKER COMBINATIONS FOR DETERMINING AGGRESSIVE PROSTATE CANCER | Minomic International Ltd. | POHNERT, STEVEN C | 1683 | §101§103§112DPOther | Non-Final OA | 77d | Pending | Dec 13, 2022 |
| 18008391 | IDENTIFICATION OF LOW-DENSITY INFLAMMATORY NEUTROPHILS IN SEVERE COVID-19 PATIENTS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. | WANG, RUIXUE | 1672 | §101§102§112 | Non-Final OA | 20d | Pending | Dec 05, 2022 |
| 17928535 | METHOD FOR PROVIDING CORROSION PROTECTION TO A PRESSURIZED WATER-STEAM SYSTEM | Kurita Water Industries Ltd. | DIAZ, MATTHEW R | 1761 | §103§112 | Final Rejection | 51d overdue | Pending | Nov 29, 2022 |
| 17923171 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | The Scripps Research Institute | SCHACHERMEYER, SAMANTHA LYNN | 1693 | §102§103 | Non-Final OA | 65d | Pending | Nov 03, 2022 |
| 17918448 | GUANIDINE-MODIFIED C-TERMINUS VANCOMYCIN COMPOUNDS, COMPOSITIONS AND METHODS | The Scripps Research Institute | REYNOLDS, FRED H | 1658 | §103Other | Final Rejection | 30d overdue | Pending | Oct 12, 2022 |
| 17910657 | SUNFLOWER PHOSPHOLIPID COMPOSITION CONTAINING PHOSPHATIDYLCHOLINE | Lipoid GmbH | ZILBERING, ASSAF | 1792 | §103 | Non-Final OA | — | Pending | Sep 09, 2022 |
| 17797644 | METHODS FOR THE TREATMENT OF HUNTER SYNDROME | Denali Therapeutics Inc. | CHANDRA, GYAN | 1674 | §103DP | Final Rejection | 37d overdue | Pending | Aug 04, 2022 |
| 17784879 | ABS RUBBER POWDER WITH LOW IMPURITY CONTENT, PREPARATION METHOD THEREFOR, AND ABS RESIN | Wanhua Chemical Group Co., Ltd. | BLAND, ALICIA | 1759 | §103 | Final Rejection | 19d | Pending | Jun 13, 2022 |
| 17706919 | SARS-CoV-2 SPIKE ECTODOMAIN POLYPEPTIDES AND COMPOSITIONS AND METHODS THEREOF | Regents Of The University Of Minnesota | EVANS, CHRISTOPHER RYAN | 1677 | §103 | Final Rejection | — | Pending | Mar 29, 2022 |
| 17631209 | PROCESS FOR PREPARING THE CRYSTALLINE FORM II OF SOTAGLIFLOZIN | Lexicon Pharmaceuticals, Inc. | BERRY, LAYLA D | 1693 | §112Other | Non-Final OA | 53d | Pending | Jan 28, 2022 |
| 17533991 | HYDROGEL-BASED 3D CELL TRAINING BIOREACTOR | The Chinese University of Hong Kong | HURST, JONATHAN M | 1799 | §103 | Final Rejection | 8d overdue | Pending | Nov 23, 2021 |
| 17296506 | METHODS FOR TREATING DYSREGULATED LIPID METABOLISM | Denali Therapeutics Inc. | AEDER, SEAN E | 1642 | §103 | Final Rejection | 15d overdue | Pending | May 24, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial